Details of the Drug

General Information of Drug (ID: DM1YBRM)

Drug Name

Cyclobenzaprine

Synonyms

Ciclobenzaprina; Cyclobenz; Cyclobenzaprinum; Fexmid; Flexeril; Lisseril; Proeptatriene; Proheptatrien; Proheptatriene; Yurelax; Cyclobenzaprine [INN]; Flexeril hydrochloride; Proeptatriene [Italian]; MK 130; NCI78206; Amrix (TN); Ciclobenzaprina [INN-Spanish]; Cyclobenzaprine (INN); Cyclobenzaprinum [INN-Latin]; Fexmid(TN); Flexeril (TN); MK-130 HCl; Ro 4-1577; Apo-Cyclobenzaprine (TN); N,N-Dimethyl-3-(dibenzo(a,d)cycloheptene-4-ylidene)propylamine; N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine; N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine; 1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-(9CI); 10,11-Dehydroamitriptyline; 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene [Italian]; 9715 R.P; 9715 R.P.

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1], [2]

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

275.4

Topological Polar Surface Area (xlogp)

5.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 177 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 5-35 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance: The clearance of drug is 0.7 L/min [5]
Elimination: After administration of a radio-labeled dose of cyclobenzaprine, 38-51% of radioactivity was excreted in the urine while 14-15% was excreted in the feces [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 18 hours [5]
Metabolism: The drug is metabolized via the liver [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.374 micromolar/kg/day [8]
Vd: The volume of distribution (Vd) of drug is 146 L [9]
Water Solubility: The ability of drug to dissolve in water is measured as 200 mg/mL [4]

Chemical Identifiers

Formula: C20H21N
IUPAC Name: N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine
Canonical SMILES: CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31
InChI: InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
InChIKey: JURKNVYFZMSNLP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2895
ChEBI ID: CHEBI:3996
CAS Number: 303-53-7
DrugBank ID: DB00924
TTD ID: D01KHH
INTEDE ID: DR0390
ACDINA ID: D00156

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2 receptor (5HT2R)	TTYSN63	NOUNIPROTAC	Antagonist	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cyclobenzaprine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Sertraline.	Depression [6A70-6A7Z]	[48]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Vilazodone.	Depression [6A70-6A7Z]	[48]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Nefazodone.	Depression [6A70-6A7Z]	[48]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Selegiline.	Depression [6A70-6A7Z]	[49]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Vortioxetine.	Depression [6A70-6A7Z]	[48]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Isocarboxazid.	Depression [6A70-6A7Z]	[49]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Milnacipran.	Depression [6A70-6A7Z]	[48]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Escitalopram.	Depression [6A70-6A7Z]	[48]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Desvenlafaxine.	Depression [6A70-6A7Z]	[48]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and OPC-34712.	Depression [6A70-6A7Z]	[50]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Doxepin.	Depression [6A70-6A7Z]	[51]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Maprotiline.	Depression [6A70-6A7Z]	[50]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Cyclobenzaprine and Esketamine.	Depression [6A70-6A7Z]	[52]
-----------


⏷ Show the Full List of 13 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cyclobenzaprine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[49]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Cyclobenzaprine and Oliceridine.	Acute pain [MG31]	[53]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[54]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[54]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Memantine.	Alzheimer disease [8A20]	[50]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Cyclobenzaprine when combined with Rivastigmine.	Alzheimer disease [8A20]	[55]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[48]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Cyclobenzaprine caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[56]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Cariprazine.	Bipolar disorder [6A60]	[50]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Cyclobenzaprine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[57]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Cyclobenzaprine when combined with Acetylcholine.	Cataract [9B10]	[58]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[59]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[59]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Cyclobenzaprine and Dihydrocodeine.	Chronic pain [MG30]	[60]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Cyclobenzaprine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[61]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Mepenzolate.	Digestive system disease [DE2Z]	[50]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[51]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Oxybutynine.	Discovery agent [N.A.]	[50]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[50]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Solifenacin.	Functional bladder disorder [GC50]	[50]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Tolterodine.	Functional bladder disorder [GC50]	[50]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Cyclobenzaprine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[62]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Cyclobenzaprine when combined with Pilocarpine.	Glaucoma [9C61]	[58]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Procarbazine.	Hodgkin lymphoma [2B30]	[49]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Cyclobenzaprine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Teriflunomide	DMQ2FKJ	Moderate	Increased metabolism of Cyclobenzaprine caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[52]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Cyclobenzaprine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[64]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Cyclobenzaprine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[65]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and ITI-007.	Insomnia [7A00-7A0Z]	[50]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Cyclobenzaprine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[66]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Cyclobenzaprine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[55]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Cyclobenzaprine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[67]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Cyclobenzaprine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[68]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Cyclobenzaprine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[69]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Cyclobenzaprine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[70]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Cyclobenzaprine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[71]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Cyclobenzaprine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[72]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Cyclobenzaprine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[73]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Cyclobenzaprine and Flibanserin.	Mood disorder [6A60-6E23]	[74]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Cyclobenzaprine and Thalidomide.	Multiple myeloma [2A83]	[75]
Ozanimod	DMT6AM2	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Ozanimod.	Multiple sclerosis [8A40]	[76]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Cyclobenzaprine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[77]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Phenindamine.	Nasopharyngitis [CA00]	[50]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Dimenhydrinate.	Nausea/vomiting [MD90]	[50]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Promethazine.	Nausea/vomiting [MD90]	[50]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Cyclizine.	Nausea/vomiting [MD90]	[50]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Cyclobenzaprine and Bupropion.	Nicotine use disorder [6C4A]	[78]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Dexfenfluramine.	Obesity [5B80-5B81]	[48]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Cyclobenzaprine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[60]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Cyclobenzaprine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[52]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Cyclobenzaprine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[79]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Cyclobenzaprine and Oxymorphone.	Pain [MG30-MG3Z]	[53]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Cyclobenzaprine and Dezocine.	Pain [MG30-MG3Z]	[53]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Flavoxate.	Pain [MG30-MG3Z]	[50]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Cyclobenzaprine and Hydrocodone.	Pain [MG30-MG3Z]	[53]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Cyclobenzaprine and Safinamide.	Parkinsonism [8A00]	[76]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Orphenadrine.	Parkinsonism [8A00]	[50]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Cyclobenzaprine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[80]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Methylscopolamine.	Peptic ulcer [DA61]	[50]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Cyclobenzaprine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[81]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[50]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Cyclobenzaprine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[82]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Quetiapine.	Schizophrenia [6A20]	[50]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Mesoridazine.	Schizophrenia [6A20]	[50]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Aripiprazole.	Schizophrenia [6A20]	[50]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Iloperidone.	Schizophrenia [6A20]	[50]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Paliperidone.	Schizophrenia [6A20]	[50]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Molindone.	Schizophrenia [6A20]	[50]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Thiothixene.	Schizophrenia [6A20]	[50]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Asenapine.	Schizophrenia [6A20]	[50]
Armodafinil	DMGB035	Minor	Increased metabolism of Cyclobenzaprine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[83]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Cyclobenzaprine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[84]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[50]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[54]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Cyclobenzaprine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[50]
-----------


⏷ Show the Full List of 75 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate	E00671	Not Available	Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Certolake sunset yellow	E00351	61817	Colorant
Colcothar yellow	E00436	518696	Colorant
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 33 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Cyclobenzaprine 30 mg capsule	30 mg	24 HR Extended Release Oral Capsule	Oral
Cyclobenzaprine 7.5 mg tablet	7.5 mg	Oral Tablet	Oral
Cyclobenzaprine 15 mg capsule	15 mg	24 HR Extended Release Oral Capsule	Oral
Cyclobenzaprine Hydrochloride 5mg tablet	5mg	Tablet	Oral
Cyclobenzaprine Hydrochloride 10mg tablet	10mg	Tablet	Oral
Cyclobenzaprine 10 mg tablet	10 mg	Oral Tablet	Oral
Cyclobenzaprine 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7152).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021777.
3	FDA Approved Drugs: Cyclobenzaprine
4	BDDCS applied to over 900 drugs
5	Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. J Clin Pharmacol. 2002 Jan;42(1):61-9. doi: 10.1177/0091270002042001007.
6	DPD Approved Drugs: Cyclobenzaprine
7	Guerlavais V, Boeglin D, Mousseaux D, Oiry C, Heitz A, Deghenghi R, Locatelli V, Torsello A, Ghe C, Catapano F, Muccioli G, Galleyrand JC, Fehrentz JA, Martinez J: New active series of growth hormone secretagogues. J Med Chem. 2003 Mar 27;46(7):1191-203.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Brioschi TM, Schramm SG, Kano EK, Koono EE, Ching TH, Serra CH, Porta V: Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. Biomed Res Int. 2013;2013:281392. doi: 10.1155/2013/281392. Epub 2013 Sep 16.
10	Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
11	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
22	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
23	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
24	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
25	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
26	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
27	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
28	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
29	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
30	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
31	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
32	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
33	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
34	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
35	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
36	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
37	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
38	5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
39	Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
40	Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
41	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
42	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
43	Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
44	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
45	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
46	Clinical pipeline report, company report or official report of Anamar.
47	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
48	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
49	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
50	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
51	Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
52	Cerner Multum, Inc. "Australian Product Information.".
53	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
54	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
55	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
56	Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
57	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
58	Multum Information Services, Inc. Expert Review Panel.
59	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
60	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
61	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
62	Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
63	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
64	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
65	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
66	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
67	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
68	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
69	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
70	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
71	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
72	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
73	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
74	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
75	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
76	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
77	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
78	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
79	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
80	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
81	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
82	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
83	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
84	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.